Malin Corporation PLC Altan files New Drug Application with US FDA (4031P)
February 07 2019 - 7:23AM
UK Regulatory
TIDM0Y71
RNS Number : 4031P
Malin Corporation PLC
07 February 2019
Malin Corporation plc
("Malin")
Altan files New Drug Application for Acetaminophen solution with
US FDA
- Malin owns approximately 65% of Altan, a Malin revenue-generative Growth Potential Asset -
Dublin-Ireland, 7 February 2019: Malin Corporation plc (Euronext
Dublin:MLC), a company investing in highly innovative life sciences
companies, is pleased to note that its subsidiary company, Altan
Pharma Limited ("Altan"), has submitted a New Drug Application
(NDA) for its formulation of acetaminophen (paracetamol) solution
for infusion to the US Food and Drug Administration (FDA) which has
been accepted for review.
Altan's intravenous solution is an analgesic used for the
treatment of pain and reduction of fever; and offers hospitals more
choices for non-opioid forms of pain relief. The formulation is
uniquely packaged in safe and flexible containers, often preferred
by healthcare providers and has sold more than 200 million units in
non-US markets to date.
"We believe this non-opioid form of pain-relief represents a
significant commercial opportunity in the US market; and has the
potential to offer a favourable product and a more economic
solution for hospitals, patients and payors" said Darragh Lyons,
Chief Business and Financial Officer of Malin.
Malin owns approximately 65% of Altan.
A copy of Altan's press release is available to view here:
http://altanpharma.com/altan-pharma-submits-new-drug-application-for-acetaminophen-solution-for-infusion-for-treatment-of-pain-and-reduction-of-fever/
ENDS
For further information, please contact:
Malin
Jessica Bergin, Director of Investor Relations & External
Reporting
Tel: +353 (0)1 901 5700
investorrelations@malinplc.com
Consilium Strategic Communications (Financial PR)
Mary-Jane Elliott / Jonathan Birt
Tel: +44 (0)20 3709 5700
malin@consilium-comms.com
Powerscourt (Ireland PR)
Eavan Gannon
Tel: +353 87 236 5973
malin@powerscourt-group.com
Davy Corporate Finance (Euronext Growth Adviser)
Brian Garrahy / Daragh O'Reilly
Tel: +353 1 679 6363
About Malin Corporation plc
Malin (Euronext Dublin:MLC) is a company investing in highly
innovative life sciences companies. Its purpose is to create
shareholder value through the application of long-term capital and
operational and strategic expertise to a diverse range of global
healthcare businesses. Malin has a focus on innovative businesses
underpinned by exceptional science and works with its investee
companies, providing strategic and financial support to enable them
to reach their value potential. Malin is headquartered and
domiciled in Ireland and listed on Euronext Growth Dublin. For more
information visit www.malinplc.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCUGUUPPUPBGPM
(END) Dow Jones Newswires
February 07, 2019 07:23 ET (12:23 GMT)
Malin (LSE:0Y71)
Historical Stock Chart
From Jun 2024 to Jul 2024
Malin (LSE:0Y71)
Historical Stock Chart
From Jul 2023 to Jul 2024